WO2002012294A3 - Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof - Google Patents

Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof Download PDF

Info

Publication number
WO2002012294A3
WO2002012294A3 PCT/US2001/024795 US0124795W WO0212294A3 WO 2002012294 A3 WO2002012294 A3 WO 2002012294A3 US 0124795 W US0124795 W US 0124795W WO 0212294 A3 WO0212294 A3 WO 0212294A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
nucleic acids
ema
group
streptococcal
Prior art date
Application number
PCT/US2001/024795
Other languages
French (fr)
Other versions
WO2002012294A2 (en
Inventor
Elisabeth Adderson
John Bohnsack
Original Assignee
St Jude Childrens Res Hospital
Univ Utah Res Found
Elisabeth Adderson
John Bohnsack
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Jude Childrens Res Hospital, Univ Utah Res Found, Elisabeth Adderson, John Bohnsack filed Critical St Jude Childrens Res Hospital
Priority to CA002417357A priority Critical patent/CA2417357A1/en
Priority to US10/333,002 priority patent/US7128919B2/en
Priority to DK01959633T priority patent/DK1320542T3/en
Priority to EP01959633A priority patent/EP1320542B9/en
Priority to DE60128115T priority patent/DE60128115T2/en
Priority to AU2001281168A priority patent/AU2001281168A1/en
Publication of WO2002012294A2 publication Critical patent/WO2002012294A2/en
Publication of WO2002012294A3 publication Critical patent/WO2002012294A3/en
Priority to US11/493,705 priority patent/US7645577B2/en
Priority to US12/632,269 priority patent/US7892552B2/en
Priority to US13/030,660 priority patent/US8529912B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

This invention provides isolated nucleic acids encoding polypeptides comprising amino acid sequences of streptococcal matrix adhesion (Ema) polypeptides. The invention provides nucleic acids encoding Group B streptococcal Ema polypeptides EmaA, EmaB, EmaC, EmaD and EmaE. The present invention provides isolated polypeptides comprising amino acid sequences of Group B streptococcal polypeptides EmaA, EmaB, EmaC, EmaD and EmaE, including analogs, variants, mutants, derivatives and fragments thereof. Ema homologous polypeptides from additional bacterial species, including S. pneumoniae, S. pyogenes, E. faecalis and C. diptheriae are also provided. Antibodies to the Ema polypeptides and immunogenic fragments thereof are also provided. The present invention relates to the identification and prevention of infections by virulent forms of streptococci. This invention provides pharmaceutical compositions, immunogenic compositions, vaccines, and diagnostic and therapeutic methods of use of the isolated polypeptides, antibodies thereto, and nucleic acids. Assays for compounds which modulate the polypeptides of the present invention for use in therapy are also provided.
PCT/US2001/024795 2000-08-08 2001-08-08 Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof WO2002012294A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002417357A CA2417357A1 (en) 2000-08-08 2001-08-08 Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
US10/333,002 US7128919B2 (en) 2000-08-08 2001-08-08 Group B streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
DK01959633T DK1320542T3 (en) 2000-08-08 2001-08-08 Group B streptococcal polypeptide nucleic acids and therapeutic compositions and vaccines thereof
EP01959633A EP1320542B9 (en) 2000-08-08 2001-08-08 Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
DE60128115T DE60128115T2 (en) 2000-08-08 2001-08-08 GROUP-B STREPTOCOCCUS POLYPEPTIDES, NUCLEIC ACID, THERAPEUTIC COMPOSITIONS AND VACCINES THEREOF
AU2001281168A AU2001281168A1 (en) 2000-08-08 2001-08-08 Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
US11/493,705 US7645577B2 (en) 2000-08-08 2006-07-26 Group B streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
US12/632,269 US7892552B2 (en) 2001-08-08 2009-12-07 Group B Streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
US13/030,660 US8529912B2 (en) 2000-08-08 2011-02-18 Group B Streptococcus polypeptides, nucleic acids and therapeutic compositions and vaccines thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63434100A 2000-08-08 2000-08-08
US09/634,341 2000-08-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US63434100A Continuation 2000-08-08 2000-08-08

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10333002 A-371-Of-International 2001-08-08
US11/493,705 Continuation US7645577B2 (en) 2000-08-08 2006-07-26 Group B streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof

Publications (2)

Publication Number Publication Date
WO2002012294A2 WO2002012294A2 (en) 2002-02-14
WO2002012294A3 true WO2002012294A3 (en) 2003-04-10

Family

ID=24543390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/024795 WO2002012294A2 (en) 2000-08-08 2001-08-08 Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof

Country Status (11)

Country Link
US (2) US7128919B2 (en)
EP (2) EP1810978B1 (en)
AT (1) ATE360640T1 (en)
AU (1) AU2001281168A1 (en)
CA (1) CA2417357A1 (en)
CY (1) CY1107702T1 (en)
DE (1) DE60128115T2 (en)
DK (1) DK1320542T3 (en)
ES (1) ES2286133T3 (en)
PT (1) PT1320542E (en)
WO (1) WO2002012294A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8858957B2 (en) 2007-09-12 2014-10-14 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2277894A1 (en) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A & B
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2004018646A2 (en) * 2002-08-26 2004-03-04 Chiron Corporation Conserved and specific streptococcal genomes
JP4875490B2 (en) 2003-07-31 2012-02-15 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Immunogenic composition for Streptococcus pyogenes
WO2005017093A2 (en) * 2003-08-15 2005-02-24 Id Biomedical Corporation Polypeptides of streptococcus pyogenes
WO2006078318A2 (en) * 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
EP1786908B1 (en) * 2004-08-18 2010-03-03 Bayer CropScience AG Plants with increased plastidic activity of r3 starch-phosphorylating enzyme
JP2008544949A (en) * 2004-10-08 2008-12-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Immunostimulatory and therapeutic compositions for pyogenic streptococci
EP1812057A4 (en) 2004-11-01 2009-07-22 Brigham & Womens Hospital Modified streptococcal polysaccharides and uses thereof
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
US20100015168A1 (en) * 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
AU2007348285A1 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
AU2008339551B2 (en) * 2007-12-21 2013-10-24 Glaxosmithkline Biologicals S.A. Mutant forms of streptolysin O
EP2381953A4 (en) 2009-01-06 2016-06-29 C3 Jian Inc Targeted antimicrobial moieties
CN103897045A (en) * 2009-01-12 2014-07-02 诺华股份有限公司 Cna_b domain antigens in vaccines against gram positive bacteria
JP2014502595A (en) * 2010-12-10 2014-02-03 メルク・シャープ・アンド・ドーム・コーポレーション A novel formulation that mitigates agitation-induced aggregation of immunogenic compositions
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CA3139257A1 (en) 2019-05-10 2020-11-19 Glaxosmithkline Biologicals Sa Conjugate production
CN115287244B (en) * 2022-06-28 2023-07-25 北部湾大学 Mutant strain with LRR structural domain knockout of streptococcus agalactiae interalin gene, and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998038312A1 (en) * 1996-02-29 1998-09-03 Washington University Bacterial elastin binding protein, nucleic acid sequence encoding same and diagnostic and therapeutic methods of use thereof
WO2000012132A1 (en) * 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
USRE31006E (en) 1968-09-24 1982-08-03 Akzona Incorporated Process for the demonstration and determination of reaction components having specific binding affinity for each other
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4356263A (en) 1980-06-09 1982-10-26 President And Fellows Of Harvard College Method of making a polysaccharide vaccine
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5302386A (en) 1986-04-16 1994-04-12 Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines and methods of manufacture
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
ATE135370T1 (en) 1988-12-22 1996-03-15 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5648241A (en) 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
US5139749A (en) 1990-06-22 1992-08-18 Tas, Inc. Fluidized calcining process
AU1570292A (en) 1991-02-07 1992-09-07 Board Of Trustees Of The University Of Illinois, The Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
CA2082951C (en) 1991-03-15 1999-12-21 Robert M. Platz Pulmonary administration of granulocyte colony stimulating factor
ZA937034B (en) 1992-09-24 1995-06-23 Brigham & Womens Hospital Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
IL107103A (en) 1992-09-24 2001-03-19 Brigham & Womens Hospital Multivalent vaccine based on conjugated molecule comprising a capsular polysaccharide linked to a protein and a method for the preparation thereof
ES2204921T3 (en) 1993-05-27 2004-05-01 Selectide Corporation SOLID PHASE LIBRARIES CODED, TOPOLOGICALLY SECREGATED.
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
WO1998050554A2 (en) 1997-05-06 1998-11-12 Human Genome Sciences, Inc. Enterococcus faecalis polynucleotides and polypeptides
CA2337102A1 (en) 1998-07-27 2000-02-10 Richard William Falla Le Page Nucleic acids and proteins from group b streptococcus
DE69935986D1 (en) 1998-07-27 2007-06-14 Sanofi Pasteur Ltd STREPTOCOCCUS PNEUMONIAE PROTEINS AND NUCLEIC ACIDS
WO2000062804A2 (en) 1999-04-15 2000-10-26 The Regents Of The University Of California Identification of sortase gene
WO2000078787A1 (en) 1999-06-21 2000-12-28 University Of Utah Research Foundation ISOLATED GENES FROM VIRULENT GROUP B $i(STREPTOCOCCUS AGALACTIAE)
US9002545B2 (en) 2011-01-07 2015-04-07 Wabtec Holding Corp. Data improvement system and method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998038312A1 (en) * 1996-02-29 1998-09-03 Washington University Bacterial elastin binding protein, nucleic acid sequence encoding same and diagnostic and therapeutic methods of use thereof
WO2000012132A1 (en) * 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
PATTI J M ET AL: "CRITICAL RESIDUES IN THE LIGAND-BINDING SITE OF THE STAPHYLOCOCCUS AUREUS COLLAGEN-BINDING ADHESIN (MSCRAMM)", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 270, no. 20, 19 May 1995 (1995-05-19), pages 12005 - 12011, XP002044191, ISSN: 0021-9258 *
PATTI J M ET AL: "MSCRAMM-MEDIATED ADHERENCE OF MICROORGANISMS TO HOST TISSUES", ANNUAL REVIEW OF MICROBIOLOGY, ANNUAL REVIEWS INC., PALO ALTO, CA, US, vol. 48, 1994, pages 585 - 617, XP001037269, ISSN: 0066-4227 *
RICARDO MANGANELLI ET AL.: "Characterization of emb, a gene encoding the major adhesin of Streptococcus defectivus", INFECTION AND IMMUNITY, vol. 67, no. 1, January 1999 (1999-01-01), pages 50 - 56, XP002211581 *
RICH R L ET AL: "ACE IS A COLLAGEN-BINDING MSCRAMM FROM ENTEROCOCCUS FAECALIS", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 38, 17 September 1999 (1999-09-17), pages 26939 - 26945, XP002930358, ISSN: 0021-9258 *
SPELLERBERG B ET AL: "LMB, A PROTEIN WITH SIMILARITIES TO THE LRAI ADHESIN FAMILY, MEDIATES ATTACHMENT OF STREPTOCOCCUS AGALACTIAE TO HUMAN LAMININ", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 67, no. 2, February 1999 (1999-02-01), pages 871 - 878, XP000973065, ISSN: 0019-9567 *
VERED OZERI ET AL.: "A two-domain mechanism for group A streptococcal adherence through protein F to the extracellular matrix", THE EMBO JOURNAL, vol. 15, no. 5, 1996, pages 989 - 998, XP002211582 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
US8858957B2 (en) 2007-09-12 2014-10-14 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
US9102741B2 (en) 2007-09-12 2015-08-11 Novartis Ag GAS57 mutant antigens and GAS57 antibodies

Also Published As

Publication number Publication date
CA2417357A1 (en) 2002-02-14
EP1320542B1 (en) 2007-04-25
US20040071729A1 (en) 2004-04-15
CY1107702T1 (en) 2013-04-18
DK1320542T3 (en) 2007-09-10
WO2002012294A2 (en) 2002-02-14
EP1810978B1 (en) 2013-02-13
US7128919B2 (en) 2006-10-31
PT1320542E (en) 2007-08-06
US20070178116A1 (en) 2007-08-02
ATE360640T1 (en) 2007-05-15
DE60128115D1 (en) 2007-06-06
DE60128115T2 (en) 2008-03-06
AU2001281168A1 (en) 2002-02-18
ES2286133T3 (en) 2007-12-01
EP1320542A2 (en) 2003-06-25
EP1320542B9 (en) 2007-09-12
EP1810978A3 (en) 2007-10-24
US7645577B2 (en) 2010-01-12
EP1810978A2 (en) 2007-07-25

Similar Documents

Publication Publication Date Title
WO2002012294A3 (en) Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
IL264925A (en) An isolated or recombinant protein capable of raising an immune response against s. pyogenes, compositions and uses thereof
KR20070101197A (en) Genes and proteins, and their use
CA2356836A1 (en) Novel streptococcus antigens
WO2002083855A3 (en) Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
HUP0500459A2 (en) Streptococcus suis vaccines and diagnostic tests
WO2001081380A3 (en) Immunogenic pneumococcal protein and vaccine compositions thereof
WO2004020609A3 (en) Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
WO2001046225A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
US8445001B2 (en) Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
WO2001096379A3 (en) Immunization of dairy cattle with chimeric gapc protein against streptococcus infection
Chessa et al. Genetic immunization with the immunodominant antigen P48 of Mycoplasma agalactiae stimulates a mixed adaptive immune response in BALBc mice
EP2450053A1 (en) Novel antigen of enterococcal pathogens and use thereof as vaccine component for therapy and/or prophylaxis
KR20080052693A (en) Genes and proteins, and their uses
US20240051995A1 (en) Antibacterial agents
NZ512448A (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
WO2002022825A3 (en) The c. albicans tec1 gene (catec1) and the coded tec1p protein
NZ543923A (en) Pho3-18 for a theraputic use, particulary in bacterial infection.
EP0838523A3 (en) RsbW-1 derived from Staphylococcus
WO2001036457A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2417357

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001959633

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001959633

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10333002

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2001959633

Country of ref document: EP